Rocket Pharmaceuticals Reports Positive Early Safety Update for RP-A501 Phase 2 Trial in Danon Disease
Rocket Pharmaceuticals, Inc. has announced encouraging early safety results from the first three patients treated under the modified protocol of its global pivotal Phase 2 clinical trial evaluating RP-A501, the company’s investigational gene therapy for Danon disease. The update marks an important milestone for the clinical program following protocol modifications designed in collaboration with regulatory authorities and scientific experts to optimize the therapy’s safety profile while maintaining its therapeutic potential.
According to the company, the initial patients treated under the revised protocol have shown promising early safety outcomes, with no evidence of serious treatment-related complications that had previously been areas of concern. Based on these findings, Rocket Pharmaceuticals is actively working with the U.S. Food and Drug Administration (FDA) to determine the pathway for enrolling additional patients and completing the pivotal study.
The company expects to provide further information regarding the regulatory pathway during the second half of 2026 as discussions with the FDA continue.
Advancing a Gene Therapy for a Rare and Devastating Disease
RP-A501 is being developed as a one-time gene therapy for Danon disease, a rare, inherited genetic disorder that primarily affects the heart, skeletal muscles, and, in some cases, cognitive function. The disease is caused by mutations in the LAMP2 gene, leading to severe impairment in the body’s ability to recycle cellular waste through the lysosomal pathway.
Patients with Danon disease often develop rapidly progressive cardiomyopathy, which can result in heart failure, life-threatening arrhythmias, and the need for heart transplantation at a young age. The condition disproportionately affects males, who typically experience earlier disease onset and faster progression than females.
Currently, there are no approved therapies that address the underlying genetic cause of Danon disease. Standard treatment focuses on managing symptoms and delaying disease progression, making gene therapy an attractive strategy for addressing the root cause of the disorder.
RP-A501 is designed to deliver a functional copy of the LAMP2 gene directly to cardiac muscle cells, with the goal of restoring normal protein production and improving heart function.
Modified Phase 2 Protocol Demonstrates Encouraging Early Safety
The latest update concerns the first three participants treated under a revised dosing and immunomodulation protocol implemented following consultation with regulatory authorities and external scientific experts.
Under the modified protocol, each patient received RP-A501 at a recalibrated dose of:
3.8 × 10¹³ genome copies (GC) per kilogram
The revised treatment strategy also incorporates an enhanced immunomodulatory regimen intended to reduce immune-related complications associated with gene therapy administration.
Patients received a combination of:
- Rituximab
- Sirolimus
- Corticosteroids
These medications are intended to suppress immune responses that could interfere with treatment or contribute to adverse events following administration of the viral vector used to deliver the therapeutic gene.
To further enhance safety, treatments were administered sequentially, with a minimum interval of four weeks between patient infusions. This staggered approach enables investigators to closely monitor each participant before proceeding with treatment of subsequent patients.
No Major Safety Concerns Observed
Rocket Pharmaceuticals reported that early safety observations have been favorable across all three patients treated under the revised protocol.
Importantly, investigators have not observed several serious complications that can occur following certain gene therapies.
Specifically, there have been no reports of:
- Thrombotic microangiopathy (TMA)
- Capillary leak syndrome
- Other significant treatment-related safety concerns
Thrombotic microangiopathy is a rare but potentially severe complication involving damage to small blood vessels that can affect kidney function and other organs. Capillary leak syndrome is another uncommon but serious condition characterized by leakage of fluid from blood vessels into surrounding tissues, potentially resulting in low blood pressure and organ dysfunction.
The absence of these complications in the initial patients provides encouraging evidence supporting the modified treatment strategy.
While follow-up remains ongoing, the early findings suggest that the protocol adjustments may have improved the therapy’s safety profile.
Phase 2 Trial Designed to Support Registration
Rocket’s pivotal Phase 2 trial has been designed as a single-arm, global study enrolling 12 patients with Danon disease.
The trial aims to further evaluate:
- Safety
- Tolerability
- Gene expression
- Cardiac outcomes
- Overall clinical benefit
Because Danon disease is an ultra-rare disorder with limited treatment options, studies of this size are common within rare disease drug development programs.
The Phase 2 trial builds upon encouraging efficacy observations reported during earlier clinical studies of RP-A501.
Completion of the trial is expected to provide key clinical data supporting future regulatory discussions regarding potential marketing approval.
Building on Positive Phase 1 Results
Rocket Pharmaceuticals continues to express confidence in RP-A501 based largely on results generated during its earlier Phase 1 clinical program.
Previous studies demonstrated promising improvements in measures of cardiac structure and function following treatment, supporting the potential for gene replacement therapy to alter the natural course of Danon disease.
These findings helped establish RP-A501 as one of the leading investigational gene therapies for inherited cardiomyopathies.
The current Phase 2 study is intended to further confirm these earlier observations while incorporating refinements designed to optimize patient safety.
CEO Highlights Confidence in the Program
Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals, described the early safety findings as an encouraging step forward for the company’s lead cardiovascular gene therapy program.
He noted that the absence of significant safety concerns among the first three patients treated under the modified protocol reinforces confidence in RP-A501 and the broader scientific rationale supporting the therapy.
According to Dr. Shah, the company’s confidence is built upon the transformative clinical findings observed during the Phase 1 trial, which demonstrated the potential for gene therapy to address the underlying genetic cause of inherited cardiomyopathies rather than simply treating symptoms.
He added that Rocket is working closely with the FDA to establish a clear pathway for completing the Phase 2 trial as efficiently as possible.
Dose Recalibration Designed to Optimize Benefit-Risk Balance
Rocket’s Chief Medical Officer, Syed Rizvi, M.D., explained the rationale behind the revised dosing strategy.
According to Dr. Rizvi, the recalibrated Phase 2 dose was selected with the expectation that it would maintain the therapeutic activity previously observed during Phase 1 while improving the overall safety profile.
The revised dosing approach accounts for improvements in the current manufacturing process that produce a higher proportion of full viral capsids within the final drug product.
Full capsids contain the therapeutic genetic payload required for effective gene transfer, whereas empty capsids do not contribute to therapeutic activity.
Because the current manufacturing process results in greater potency, the adjusted dose is expected to deliver comparable biological activity while reducing total vector exposure.
The revised protocol was developed through collaboration with leading experts in gene therapy as well as ongoing consultation with the FDA.
Rocket believes this approach will preserve RP-A501’s clinical effectiveness while optimizing its benefit-risk profile.
Importance of Immunomodulation in Gene Therapy
Immune responses remain one of the primary challenges associated with systemic gene therapy.
Administration of viral vectors can trigger immune activation that may reduce treatment effectiveness or contribute to inflammatory complications.
To address these risks, the modified protocol includes a carefully designed immunomodulatory strategy using multiple agents with complementary mechanisms.
Rituximab targets B cells involved in antibody production, sirolimus helps regulate immune cell activation, and corticosteroids provide broad anti-inflammatory effects.
Together, these therapies aim to reduce immune-mediated complications while allowing efficient delivery of the therapeutic gene.
The encouraging early safety observations suggest that this comprehensive immunomodulatory regimen may successfully support safer administration of RP-A501.
Regulatory Discussions Continue
Rocket Pharmaceuticals is actively engaging with the FDA to determine the next steps for the clinical development program.
The company is seeking regulatory alignment regarding:
- Enrollment of additional patients
- Continuation of dosing under the revised protocol
- Completion of the pivotal Phase 2 study
- Potential future regulatory submission pathway
The company expects to provide an update regarding these discussions during the second half of 2026.
Continuing Progress in Genetic Cardiomyopathy Research
RP-A501 represents one of several advanced gene therapy programs being developed to treat inherited cardiovascular diseases by addressing their underlying genetic causes.
Unlike conventional heart failure medications that primarily manage symptoms, gene replacement therapies aim to restore normal cellular function through correction of the underlying genetic defect.
For patients with Danon disease—who currently face progressive heart failure, frequent transplantation, and significantly shortened life expectancy—successful development of RP-A501 could represent a transformative therapeutic advance.
With encouraging early safety findings under the modified Phase 2 protocol and ongoing regulatory engagement, Rocket Pharmaceuticals continues working toward completing the pivotal study and advancing RP-A501 as a potential treatment option for individuals living with this rare and life-threatening inherited disorder.
About RP-A501
RP-A501 is Rocket’s investigational gene therapy for the treatment of Danon disease and the first gene therapy for a cardiovascular condition to demonstrate safety and efficacy in clinical studies. RP-A501 has the potential to restore or stabilize cardiac function in patients with Danon disease. RP-A501 consists of a recombinant adeno-associated serotype 9 (AAV9) capsid containing a functional version of the human LAMP2B transgene (AAV9.LAMP2B) which is administered as a single intravenous (IV) infusion.
In clinical studies, RP-A501 has been shown to target cardiac cells (cardiomyocytes) and deliver the functional LAMP2B gene to heart tissue, which led to improved cardiac structure and function in patients. RP-A501 holds FDA RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations in the U.S. along with ATMP and PRIME designations in the EU.
About Danon Disease
Danon disease is a rare X-linked inherited, multi-organ lysosomal-associated disorder with a devastating clinical course. The causative mutation has been identified in the gene encoding for lysosome-associated membrane protein, otherwise known as LAMP2, an important mediator of autophagy and primarily expressed in heart, skeletal muscle and brain tissue.
This mutation results in accumulation of autophagosomes and glycogen, particularly in cardiac muscle and other tissues, which ultimately leads to heart failure, and for male patients, frequent death during adolescence or early adulthood. The only available definitive treatment option for Danon disease is cardiac transplantation, which is associated with substantial complications and is not considered curative, representing the high unmet medical need for patients with Danon disease.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, with a strategic focus on inherited cardiovascular disorders and additional programs in hematology and immunology. Rocket’s cardiovascular portfolio includes three clinical-stage gene therapy programs targeting hypertrophic, arrhythmogenic, and dilated cardiomyopathies, together representing one of the broadest pipelines focused on inherited heart disease. The Company’s integrated platform combines proprietary AAV manufacturing capabilities, extensive clinical experience in cardiac gene therapy, and long-term safety and efficacy data supporting advancement across its cardiovascular portfolio.